CINECA IRIS Institutional Research Information System

CIANCIO, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.663
EU - Europa 5.131
AS - Asia 3.103
AF - Africa 100
SA - Sud America 92
OC - Oceania 48
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.469
CN - Cina 1.766
IT - Italia 1.009
DE - Germania 1.000
IE - Irlanda 575
SE - Svezia 487
FR - Francia 360
UA - Ucraina 316
DK - Danimarca 310
SG - Singapore 272
GB - Regno Unito 246
FI - Finlandia 230
KR - Corea 205
IN - India 160
CA - Canada 154
AT - Austria 150
JP - Giappone 145
VN - Vietnam 135
TW - Taiwan 113
ID - Indonesia 93
PL - Polonia 83
RU - Federazione Russa 78
ES - Italia 67
HK - Hong Kong 64
NL - Olanda 57
BR - Brasile 50
AU - Australia 45
PK - Pakistan 32
BE - Belgio 29
RO - Romania 28
MX - Messico 27
EG - Egitto 25
GR - Grecia 25
CH - Svizzera 24
TR - Turchia 24
CO - Colombia 19
IR - Iran 19
UZ - Uzbekistan 18
KE - Kenya 16
CZ - Repubblica Ceca 13
TH - Thailandia 13
PH - Filippine 12
HR - Croazia 10
NG - Nigeria 9
PT - Portogallo 9
EC - Ecuador 8
BF - Burkina Faso 7
HU - Ungheria 7
IL - Israele 7
EU - Europa 6
GT - Guatemala 6
IQ - Iraq 6
SD - Sudan 6
AR - Argentina 5
ET - Etiopia 5
MN - Mongolia 5
PE - Perù 5
CM - Camerun 4
NO - Norvegia 4
TN - Tunisia 4
VE - Venezuela 4
ZA - Sudafrica 4
ZM - Zambia 4
GH - Ghana 3
MY - Malesia 3
MZ - Mozambico 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
YE - Yemen 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
CU - Cuba 2
GM - Gambi 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
BG - Bulgaria 1
BY - Bielorussia 1
CD - Congo 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HT - Haiti 1
LB - Libano 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
MU - Mauritius 1
MV - Maldive 1
PA - Panama 1
PS - Palestinian Territory 1
SN - Senegal 1
UG - Uganda 1
Totale 15.143
Salva come PNG Salva come JPEG
Città #
Ann Arbor 898
Chandler 784
Beijing 751
Dublin 573
Fairfield 341
Houston 319
Torino 274
Dearborn 246
Redwood City 229
Ashburn 213
Wilmington 203
Villeurbanne 199
Nyköping 191
Woodbridge 190
Singapore 189
Medford 179
Princeton 178
Jacksonville 177
Vienna 143
Guangzhou 133
Shanghai 121
Seattle 105
Cambridge 95
Jakarta 76
Pisa 74
Warsaw 72
Nanjing 68
Dong Ket 67
Hangzhou 65
Boston 61
Toronto 58
Turin 56
Milan 54
Ottawa 54
Fremont 52
Taipei 52
Chengdu 51
New York 44
Wuhan 44
Rome 43
Boardman 42
Tokyo 36
Hefei 34
Nürnberg 31
Santa Clara 31
Norwalk 27
San Diego 27
Seoul 25
Kunming 24
Los Angeles 24
Zhengzhou 24
Munich 23
Verona 23
Helsinki 22
Chongqing 21
Falls Church 20
Brussels 19
Changsha 18
Jinan 18
Pune 18
West Jordan 18
Amsterdam 17
London 17
San Mateo 17
Hebei 16
Nanchang 16
Naples 16
Washington 16
Hanoi 15
Mountain View 15
Delhi 14
Duncan 14
Fuzhou 14
Rochester 14
Central 13
Central District 13
Karachi 13
Madrid 13
Phoenix 13
Bologna 12
Gurgaon 12
Ho Chi Minh City 12
Nanning 12
Barcelona 11
Chicago 11
Lachine 11
Tianjin 11
Xiamen 11
Athens 10
Bengaluru 10
Cupertino 10
Melbourne 10
Paris 10
Hong Kong 9
Hyderabad 9
Lahore 9
Pingtung City 9
Shenyang 9
Abuja 8
Brno 8
Totale 8.727
Salva come PNG Salva come JPEG
Nome #
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 1.005
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma 566
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 510
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 357
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 355
DURABILITY OF THE RESPONSE TO PEGINTERFERON ALFA2b AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A COHORT STUDY IN THE ROUTINE CLINICAL SETTING. 315
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 310
The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta 292
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 278
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 276
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 267
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 257
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 213
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
AISF position paper on liver disease and pregnancy. 186
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 185
Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators 184
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 182
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 174
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 172
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 166
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 162
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 160
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 149
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 148
Discordant results for IL28B genotyping (rs12979860 vs. rs8099917) and the prediction of rapid viral response in chronic hepatitis C 141
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 133
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 133
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Hepatitis: PEG-IFN for the treatment of hepatitis D 121
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 116
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. 114
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 108
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma 106
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 105
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency 103
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 103
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 101
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 98
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 98
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 98
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D 96
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 96
[Cyclosporin for steroid refractory ulcerative colitis. Results of a study conducted at Turin General Hospital between 1990 and 1997] 95
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 94
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 92
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 90
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 90
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. 88
Addition of Bismuth to the Standard Triple Therapy for Helicobacter Pylori Infection 87
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 86
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 85
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin 83
Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study. 82
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D 82
DROPLET DIGITAL PCR APPLICATION FOR HEPATITIS DELTA VIREMIA QUANTIFICATION 82
Importance of HLA-B in the sustained virological response in patients with chronic hepatitis C treated with peg-IFN and ribavirin 82
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 81
TT virus infection in Italy: prevalence and genotypes in healthy subjects, viral liver diseases and asymptomatic infections by parenterally transmitted viruses. 79
Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay 76
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 76
Epithelioid haemangioendothelioma of the liver: report of a case submitted to orthotopic liver transplantation. 74
Chronic HBV related liver disease 74
Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group. 73
Practical out-patient management of autoimmune hepatitis 73
Microarrays analysis for predicting treatment response in patients with chronic hepatitis C: preliminary data 73
Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or agonist II 73
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? 73
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 73
Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response? 73
Gene expression profiles for predicting treatment response in patients with chronic hepatitis C: preliminary analysis 72
Hepatitis B-core related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D 72
RELATIONSHIP OF GENETIC VARIATIONS OF THE GENE CODING FOR THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1 (HENT1) WITH PROTEIN EXPRESSION AND RESPONSE TO TREATMENT IN CHRONIC HEPATITIS C 70
A NOVEL APPROACH FOR HEPATITIS DELTA VIRUS VIREMIA QUANTIFICATION BY DROPLET DIGITAL PCR ASSAY 70
Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alphafetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 69
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 68
Thymalfasin in the treatment of hepatitis B and C. 68
Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin 67
Epidemiology and clinical course of hepatitis delta virus infection over 15 years in a liver center in Northern Italy 67
Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. 67
Assessment of liver fibrosis in the clinical setting: something is changing? 66
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. 65
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study 65
HBV cccDNA evaluation in HBV-core antibody (HBcAb)-positive liver transplant donors 64
A deceiving case of paraplegia 64
Therapy of chronic hepatitis C: a critical review. 63
Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study. 63
Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 62
Recurrent Sweet's syndrome in reactivated Crohn's disease. 62
TREATMENT WITH INTERFERON-alfa2b OF NAIVE NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C ACCORDING TO VIRAEMIA AND GENOTYPE. RESULTS OF A RANDOMIZED MULTICENTRE STUDY 62
Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study 62
Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment 61
The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease 60
Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification 59
CROSS-SECTIONAL AND LONGITUDINAL EVALUATION OF ALPHA-FETOPROTEIN (AFP) AND PROTEIN INDUCED BY VITAMIN K ABSENCE OR ANTAGONIST II (PIVKA-II) IN PATIENTS WITH CIRRHOSIS OF VIRAL ETIOLOGY UNDER SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA (HCC) 58
Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents 58
Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. 57
Totale 13.457
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.167
article - articoli 0
book - libri 0
conference - conferenze 9.327
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.494
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.363 0 0 102 232 225 428 271 164 223 298 212 208
2020/20211.820 196 134 131 115 180 136 145 85 169 161 126 242
2021/20222.620 146 159 178 200 183 201 225 180 140 186 409 413
2022/20232.675 284 225 70 259 222 629 238 164 267 78 149 90
2023/20241.382 178 204 86 79 80 167 69 104 16 95 110 194
2024/2025338 56 167 115 0 0 0 0 0 0 0 0 0
Totale 15.733